US EditionIvermectin Mass Treatment Shows Great Promise in Reducing Malaria Transmission
KWALE COUNTY, KENYA, JUL 24 – The BOHEMIA trial with over 20,000 participants showed ivermectin reduced malaria infections by 26%, offering a promising complementary tool amid rising insecticide resistance.
- The BOHEMIA project conducted Mass Drug Administration trials using ivermectin in Kenya and Mozambique on July 24, 2025, showing significant malaria transmission reduction.
- These trials responded to rising malaria cases—263 million in 2023 with nearly 600,000 deaths annually—and decreasing effectiveness of current insecticide-based controls.
- The trials, which included more than 20,000 participants receiving monthly doses of ivermectin over three months, showed that the treatment led to a 26% decrease in the incidence of malaria infections compared to the control drug.
- Carlos Chaccour expressed strong enthusiasm about the findings, emphasizing ivermectin’s potential to enhance current malaria control strategies, while Regina Rabinovich highlighted the study’s implications for advancing malaria prevention efforts in endemic regions.
- An expert panel affiliated with the World Health Organization reviewed the study, confirmed its demonstrated impact, and suggested additional research, while health officials at the national level consider incorporating ivermectin into malaria control strategies.
12 Articles
12 Articles
A drug that inoculates in the blood a poison for malaria-transmitting mosquitoes. This idea, that of using the human body itself to kill these malaria vectors and thus reduce the transmission of this disease, is the one behind a new study published on Wednesday night in The New England Journal of Medicine. It is the clinical trial BOHEMIA, the largest research to date examining the potential of the drug ivermectin as a complementary tool for mal…
KEMRI study shows ivermectin significantly reduces malaria transmission
A study conducted by the Kenya Medical Research Institute (KEMRI), in conjunction with the Barcelona Institute for Global Health (ISGlobal) and the Manhiça Health Research Center (CISM), now shows that ivermectin, an antiparasitic drug, significantly reduces malaria infections.
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
